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Pain constitutes a major public-health problem with an
impact on both the individual and the society that is still
inadequately treated. All clinically used opioid analgesics
for severe acute and chronic pain, e.g. morphine, fentanyl
and oxycodone, are agonists activating central μ opioid
receptors. Their clinical use is associated with a number of
adverse actions, such as respiratory depression, sedation,
nausea, constipation, tolerance and addiction. One of the
major aims of medicinal chemistry and opioid pharma-
cology is to develop opioids with high affinity and/or
selectivity for the μ opioid receptor, exhibiting a favorable
dissociation between analgesia and the occurrence of side
effects. 14-Methoxymetopon, designed by our group, was
described as a highly potent and selective μ opioid agonist
with an unusual pharmacological and functional profile,
being genuinely safer than the "gold standard pain-killer"
morphine. With the aim to identify and develop scientifi-
cally proven opioid drugs with a reliable target-oriented
pharmacological profile, established efficacy and favora-
ble safety index, a new analogue of 14-methoxymetopon,
containing a benzyl substituent at position 5, was investi-
gated for its in vitro biological and in vivo pharmacological
activities. Binding affinities and selectivities to opioid
receptors were determined in rodent brain membranes
using competition binding assays. Analgesic activity after
subcutaneous (s.c.) administration was assessed in mice
using tail-flick and hot-plate tests. The rotarod test was
used to evaluate the drug effect on motor coordination. In
vitro binding studies indicated that the 5-benzyl analogue
of 14-methoxymetopon displayed high affinity and selec-
tivity at the μ opioid receptor. It showed a significant
increase in affinity (20-fold) at the μ receptor as compared
to that of morphine. The 5-benzyl derivative produced
dose-dependent analgesic effects in the tail-flick and hot-
plate tests after s.c. administration to mice. The antinocic-
eptive dose necessary to elicit a 50% effect (ED50) was 43
μg/kg in the tail-flick test and 53 μg/kg in the hot-plate
test. Compared to 14-methoxymetopon, the new ana-
logue showed comparable antinociceptive potency, while
it was about 50-fold more active than morphine. No sig-
nificant impairment of the motor performance was
induced by the novel opioid. These findings show that
introduction of a 5-benzyl substituent into 14-meth-
oxymetopon did not significantly affect the in vitro and in
vivo pharmacological properties compared to the parent
compound. The interesting pharmacological profiles of
this class of morphinans will serve as a basis for our con-
tinuing exploration of potent opioid analgesics for the
pharmacotherapy of pain.
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